Emerging transcatheter therapies for aortic and mitral disease
To the editor: One issue that has not been discussed in the paper by Christofferson et al 1 is the cost-effectiveness of transcatheter therapies, particularly those based on the new transcatheter aortic valves.
Previous cost-effectiveness studies on surgical aortic valve replacement (AVR) compared AVR with best medical therapy (or no operation) and found that AVR had an acceptable cost-effectiveness profile (cost per quality-adjusted life year gained = approximately $13 500 calculated from an incremental lifetime cost of around $110 000 per patient and an incremental lifetime benefit of 8.2 quality-adjusted life years gained per patient in a series of 4617 subjects 2 ). Likewise, the cost-effectiveness of the new transcatheter aortic valves needs to be assessed using best medical therapy as the main comparator.
As pointed out by Christofferson et al,
1
the data on the outcome expected using transcatheter aortic valves are still preliminary. Hence, inasmuch as this clinical information concerning one of the two comparators is still inconclusive, a costeffectiveness study cannot be currently undertaken to compare transcatheter aortic valves versus best medical therapy. However, some important points of controversy for future cost-effectiveness analyses are already sufficiently clear-for example: (a) the choice of appropriately matched effectiveness data for the control group given best medical therapy; and (b) the selection of similar age ranges for the two groups under comparison.
In the analysis by Wu et al, 2 both groups being compared (AVR versus no operation) were recruited over a time interval covering several decades: the 4617 subjects of the AVR group were in fact enrolled between 1961 and 2003 while the control group given best medical therapy (mean quality-adjusted survival = 1.2 years per patient) refers to information published between 1982 and 1988 (references 7 to 9 of the paper by Wu 2 ). Since these controls date back nearly 30 years, future cost-effectiveness studies on transcatheter aortic valves should exercise much caution in using this group as a historical comparator because the difference in the era of treatment between transcatheter valves (implanted in recent years) and medical therapy (assessed 30 years ago) could prove to be an artefact that falsely improves the cost-effectiveness of the new valves.
More importantly, current trends in the selection of candidates for transcatheter aortic valves 1 tend to include very elderly people (subjects aged more than 80) whose life expectancy is shorter than that of historical populations with aortic valve disease such as the one reported by Wu et al. 2 This factor (that appropriately reduces the magnitude of the incremental survival benefit resulting from the new valves) should be carefully incorporated in future cost-effectiveness analysis to avoid other artefacts favouring the new valves.
In summary, despite these risks of an imperfect match in baseline age or era of treatment or both, cost-effectiveness studies in this area are urgently needed to carefully determine whether or not these high-cost innovative devices (unit price J20 000 3 or $30 000 4 ) are value for money according to current cost-effectiveness standards. To the editor: If a study identifies several predictors of high risk for adverse events-as GRACE has attempted to do for acute coronary syndrome (ACS)-could we dare presume that the absence of those predictors might perhaps indicate low risk-that is, freedom from those events? Have we somehow missed the point of this paper by Brieger et al? 1 Or are there more analyses just waiting to be presented from a different angle to further advance our ability to manage this multifaceted condition called ACS?
